Abstract
Background
Creatinine kinase-MB (CK-MB) and cardiac troponin I (cTnI) elevations are highly specific for myonecrosis after percutaneous coronary intervention (PCI). Aspirin is used to prevent thrombotic complications. Several studies have shown that some individuals exhibit a reduced or completely missing antiplatelet response to aspirin. The aim of this study is to investigate the effects of platelet reactivity despite aspirin therapy on CK-MB and cTnI levels after elective percutaneous coronary interventions despite 600 mg loading dose of clopidogrel.
Methods
One hundred fourteen (mean age 61.2 ± 9.3 years, 78.1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study. Platelet reactivity despite aspirin was measured by platelet function analyzer (PFA)-100 collagen/epinephrine cartridge. Blood samples for CK-MB and cTnI were obtained before and at 6, 24, and 36 h after the PCI. Persistent platelet reactivity was defined when collagen/epinephrine closure time <165 s.
Results
A total of 87 (76.4%) patients were noted to have normal platelet reactivity (Group A), and 27 (23.6%) had persistent platelet reactivity (Group B). The elevations of CK-MB and cTnI levels were statistically significant within the groups (both P < 0.001). However, there were no significant differences in the CK-MB and cTnI levels of the groups at baseline and after PCI for all studied hours.
Conclusion
Persistent platelet reactivity was not associated with increased risk of CK-MB, cTnI elevations in low-to-intermediate risk PCI patients.
Similar content being viewed by others
References
Abdelmeguid AE, Topol EJ (1996) The myth of the myocardial ‘infarctlet’ during percutaneous coronary revascularization procedures. Circulation 94:3369–3375
Califf RM, Abdelmeguid AE, Kuntz RE et al (1998) Myonecrosis after revascularization procedures. J Am Coll Cardiol 31:241–251
Kanaparti PK, Brown DL (2000) Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol 86:619–622
Garbatz E, Iung B, Lefevre G et al (1999) Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 34:663–671
Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533
Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420
Popma JJ, Weitz J, Bittl JA et al (1998) Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 114:728S–741S
Patrono C, Coller B, Dalen JE et al (2001) Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 119:39S–63S
Sanderson S, Emery J, Baglin T et al (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142:370–380
Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710–1713
Mason PJ, Freedman JE, Jacobs AK (2004) Aspirin resistance: current concepts. Rev Cardiovasc Med 5:156–163
Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. JACC 6:986–993
Tantry US, Bliden KP, Gurbel PA (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:1705–1709
Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK (2006) on behalf of the platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis platelet function analyzer (PFA–100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4:312–319
Mammen EF, Comp PC, Gosselin R et al (1998) PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24:195–202
Andersen K, Hurlen M, Arnesen H et al (2003) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108:37–42
Homoncik M, Jilma B, Hergovich N et al (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316–321
Chen WH, Lee PY, Ng W et al (2004) Aspirin resistance is associated with high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122–1126
Coma-Canella I, Velasco A, Castano S (2005) Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101:71–76
Harrison P, Robinson MS, Mackie IJ et al (1999) Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 10:25–31
Heilmann EJ, Kundu SK, Sio R, Garcia C et al (1997) Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 87:159–164
Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9:407–415
Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. JACC 48:1742–1750
Gum PA, Koltke-Marchant K, Poggio ED et al (2001) Profile and prevalance of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235
Wang JC, Aucoin-Barry D, Manuelian D et al (2003) Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92:1492–1494
Abacı A, Calıskan M, Bayram F et al (2006) A new definition of aspirin non-responsiveness by Paltelet Function analyzer-100TM and its predictors. Platelets 17:7–13
Nageh T, Sherwood RA, Harris BM et al (2003) Cardiac troponin T and I and creatine-kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92:285–293
Kini AS, Lee P, Marmur JD et al (2004) Correlation of postpercutaneous coronary intervention creatine-kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 93:18–23
Kini A, Marmur J, Kini S et al (1999) Creatine-kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a bening clinical course. J Am Coll Cardiol 34:663–671
Fuchs S, Kornowski R, Mehran R et al (2000) Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 85:1077–1082
Adams JE, Bodor GS, Devile-Roman VG et al (1993) Cardiac Troponin I: a marker with high specificity for cardiac injury. Circulation 88:101–106
Amsterdam EA, Lewis WR (1998) Identification of low risk patients with chest pain in emergency department: another look at cardiac troponins. J Am Coll Cardiol 32:15–16
Varani E, Balducelli M, Vecchi G et al (2005) Occurence of non-Q myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis. J Interv Cardiol 18:243–248
Gurbel PA, Bliden KP, Zaman KA et al (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (clear platelets) study. Circulation 111:1153–1159
Kastarati A, Mehilli J, Schühlen H et al (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232–238
Mehilli J, Kastrati A, Schühlen H et al (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Circulation 110:3627–3635
Hankey GJ, Eikelboom JW (2006) Aspirin resistance. Lancet 367:606–617
Eikelboom JW, Hirsh J, Weitz JI, et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650–1655
Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965
Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder A pilot-study including 180 post-stroke patients. Thromb Res 71:397–403
Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K (2002) Towards a definition of aspirin resistance: a typological approach. Platelets 13:37–40
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gulmez, O., Yildirir, A., Kaynar, G. et al. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. J Thromb Thrombolysis 25, 239–246 (2008). https://doi.org/10.1007/s11239-007-0067-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-007-0067-z